| Bioactivity | CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects[1]. | ||||||||||||
| Invitro | CWI1-2 (0-1 μM, 24 h) 具有良好的抗白血病功效[1]。 Apoptosis Analysis[1] Cell Line: | ||||||||||||
| In Vivo | CWI1-2（5 mg/kg，i.v.，每日一次，7-10天）可显着延缓 BMT 受体 B6.SJL（CD45.1）小鼠白血病的发生和存活时间，体重无明显影响 [1]。 | ||||||||||||
| Name | CWI1-2 | ||||||||||||
| CAS | 2408590-36-1 | ||||||||||||
| Formula | C22H17Cl3N6O3 | ||||||||||||
| Molar Mass | 519.77 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hengyou Weng, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10. |
CWI1-2
CAS: 2408590-36-1 F: C22H17Cl3N6O3 W: 519.77
CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, ind
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.